



## **Synta Pharmaceuticals to Host Third-Quarter Conference Call on November 13, 2007**

November 5, 2007

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 5, 2007--Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will release its third-quarter 2007 financial results before the market opens on Tuesday, November 13, 2007.

Management will conduct a conference call at 10:00 a.m. (ET) that morning to review the company's third-quarter financial results. The conference call will be webcast live over the Internet and can be accessed by logging on to the "Investors" section of the Synta Pharmaceuticals website, [www.syntapharma.com](http://www.syntapharma.com), prior to the event.

The call also can be accessed by dialing (877) 407-8035 or (201) 689-8035 prior to the start of the call. For those unable to join the live conference call, a replay will be available from 2:00 p.m. (ET) on November 13 through midnight (ET) on November 20. To access the replay, dial (877) 660-6853 or (201) 612-7415 and refer to both account number 286 and conference ID 259672. The webcast also will be archived on the company's website.

### **About Synta Pharmaceuticals**

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were discovered and developed internally. Synta has a global collaboration agreement with GlaxoSmithKline (GSK) for the joint development and commercialization of its lead investigational drug candidate, elesclomol. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

CONTACT: Synta Pharmaceuticals Corp.  
Rob Kloppenburg, 781-541-7125  
or  
MacDougall Biomedical Communications  
Doug MacDougall, 508-647-0209

SOURCE: Synta Pharmaceuticals Corp.